Claims for Patent: 11,535,626

Summary for Patent: 11,535,626

Title:	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1 carboxamide and solid state forms thereof
Abstract:	The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
Inventor(s):	Aileen L. Pangan, Henrique D. Teixeira, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder
Assignee:	AbbVie Inc
Application Number:	US17/827,083
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,535,626
Patent Claims:	1. A method of treating a human patient having moderate to severe atopic dermatitis, comprising orally administering once daily to the patient a solid dosage form comprising (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (Compound 1) in an amount sufficient to deliver to the patient 30 mg of Compound 1 free base equivalent. 2. The method of claim 1, wherein the patient is an adult. 3. The method of claim 2, wherein the adult patient had inadequately responded to treatment with topical corticosteroids or topical calcineurin inhibitors. 4. The method of claim 1, wherein the method further comprises administering a topical corticosteroid to the patient. 5. The method of claim 1, wherein the patient has achieved clear or almost clear skin, as measured by an Investigator's Global Assessment score of 0 or 1, at week 16 of said once daily administration. 6. A method of treating a human patient having moderate to severe atopic dermatitis, comprising orally administering once daily to the patient a solid dosage form comprising (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (Compound 1) in an amount sufficient to deliver to the patient 30 mg of Compound 1 free base equivalent, wherein the method results in an Eczema Area and Severity Index (EASI) 75 at 16 weeks after the first daily administration. 7. The method of claim 6, wherein the patient is an adult. 8. The method of claim 7, wherein the adult patient had inadequately responded to treatment with topical corticosteroids or topical calcineurin inhibitors. 9. The method of claim 6, wherein the method further comprises administering a topical corticosteroid to the patient. 10. The method of claim 6, wherein the patient has achieved clear or almost clear skin, as measured by an Investigator's Global Assessment score of 0 or 1, at week 16 of said once daily administration. 11. A method of treating a human patient having moderate to severe atopic dermatitis, comprising orally administering once daily to the patient a solid dosage form comprising (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (Compound 1) in an amount sufficient to deliver to the patient 30 mg of Compound 1 free base equivalent, wherein the method results in an Eczema Area and Severity Index (EASI) 90 at 16 weeks after the first daily administration. 12. The method of claim 11, wherein the patient is an adult. 13. The method of claim 12, wherein the adult patient had inadequately responded to treatment with topical corticosteroids or topical calcineurin inhibitors. 14. The method of claim 13, wherein the method further comprises administering a topical corticosteroid to the patient. 15. The method of claim 11, wherein the patient has achieved clear or almost clear skin, as measured by an Investigator's Global Assessment score of 0 or 1, at week 16 of said once daily administration. 16. A method of treating a human patient having moderate to severe atopic dermatitis, comprising orally administering once daily to the patient a solid dosage form comprising (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (Compound 1) in an amount sufficient to deliver to the patient 30 mg of Compound 1 free base equivalent, wherein the method results in an Eczema Area and Severity Index (EASI) 100 at 16 weeks after the first daily administration. 17. The method of claim 16, wherein the patient is an adult. 18. The method of claim 17, wherein the adult patient had inadequately responded to treatment with topical corticosteroids or topical calcineurin inhibitors. 19. The method of claim 18, wherein the method further comprises administering a topical corticosteroid to the patient. 20. The method of claim 16, wherein the patient has achieved clear or almost clear skin, as measured by an Investigator's Global Assessment score of 0 or 1, at week 16 of said once daily administration.